Tag: Nice


  • Outdated NHS Guidelines Leave Cancer Patients Facing a Death Sentence, Says Ex-Minister

    Outdated NHS Guidelines Leave Cancer Patients Facing a Death Sentence, Says Ex-Minister

    UK Cancer Care Under Scrutiny as Second Transplants Denied Cancer patients facing a second stem cell transplant are being refused under current NHS guidelines, a decision condemned by former Conservative minister Sir Gavin Williamson as a potential death sentence. The debate centers on whether the National Institute for Health and Care Excellence (NICE) criteria and…

  • NICE Recommends AUCATZYL (obecabtagene autoleucel) for UK patients

    NICE Recommends AUCATZYL (obecabtagene autoleucel) for UK patients

    Summary: NICE backs AUCATZYL for eligible patients The National Institute for Health and Care Excellence (NICE) has recommended AUCATZYL, the CAR-T cell therapy obatabtagene autoleucel (also known as obecabtagene autoleucel), for use within the UK’s healthcare system. The decision marks a significant milestone for patients with certain hematologic cancers and highlights the growing role of…

  • NICE Recommends AUCATZYL® (obecabtagene autoleucel) for Wider Patient Access in the UK

    NICE Recommends AUCATZYL® (obecabtagene autoleucel) for Wider Patient Access in the UK

    Overview: NICE Endorses AUCATZYL for Expanded Use The National Institute for Health and Care Excellence (NICE) has recommended AUCATZYL® (obecabtagene autoleucel) for a broader patient population in the United Kingdom. This decision follows a rigorous review of clinical data, cost-effectiveness, and real-world impact on NHS services. AUCATZYL is a next-generation CAR-T therapy designed to harness…

  • NICE Recommends AUCATZYL for CAR-T Therapy: What It Means for Patients

    NICE Recommends AUCATZYL for CAR-T Therapy: What It Means for Patients

    Introduction: A pivotal NICE Recommendation The National Institute for Health and Care Excellence (NICE) has endorsed AUCATZYL (obecabtagene autoleucel) for use in eligible patients, signaling a major milestone for CAR-T cell therapy in the healthcare system. This endorsement places AUCATZYL among the select therapies that have gained formal approval for coverage and reimbursement, potentially expanding…

  • Ocular Melanoma Liver Chemotherapy Funding: NHS Access Challenge in Telford

    Ocular Melanoma Liver Chemotherapy Funding: NHS Access Challenge in Telford

    Hooked by a life-changing diagnosis Jamie Scott, a 49-year-old communications worker for an NHS mental health trust, was diagnosed with eye cancer (ocular melanoma) in 2011. Over the years the cancer has progressed, spreading to her liver and triggering a fierce fight not just against the disease but against the barriers that limit timely access…

  • England and Wales Set to Welcome HIV-Prevention Jab CAB-LA as Game-Changing PrEP Option

    England and Wales Set to Welcome HIV-Prevention Jab CAB-LA as Game-Changing PrEP Option

    Overview: A new chapter in HIV prevention A potential breakthrough in the fight against HIV is on the cusp of becoming standard care in England and Wales. Cabotegravir, known as CAB-LA, is an injectable pre-exposure prophylaxis (PrEP) option that could be administered every two months to reduce the risk of HIV infection among HIV-negative adults…

  • New HIV Prevention Jab Set to Transform PrEP in England and Wales

    New HIV Prevention Jab Set to Transform PrEP in England and Wales

    Overview: A New Chapter in HIV Prevention A long-awaited option for preventing HIV infection is moving closer to routine use in England and Wales. Cabotegravir (CAB-LA), a long-acting injectable that is administered every two months, is poised to become the first injectable form of PrEP (pre-exposure prophylaxis) approved by the National Institute for Health and…

  • England and Wales poised to approve game-changing HIV prevention jab

    England and Wales poised to approve game-changing HIV prevention jab

    New injectable PrEP set to reshape HIV prevention England and Wales are nearing a landmark decision that could alter the landscape of HIV prevention. A long-acting injectable drug, cabotegravir (CAB-LA), is recommended for use in adults and young people who are HIV-negative, with the aim of reducing new infections. Unlike the routine daily tablets used…

  • Nice vs Paris FC: Paris FC Fight Back After Going Behind

    Nice vs Paris FC: Paris FC Fight Back After Going Behind

    Match recap: a tense night at the Allianz Riviera Nice and Paris FC delivered a lively Ligue 1 encounter in the south of France, with the Aiglons dictating possession but the visitors showing resilience. The opening goal came just before the break when a clever sequence culminated in Diop firing home after a decisive pass…

  • Live: Nice vs Paris FC – Paris FC push for comeback after deficit

    Live: Nice vs Paris FC – Paris FC push for comeback after deficit

    Live updates from Allianz Riviera: Nice vs Paris FC Nice started this Ligue 1 clash with intent, and their pressure paid off just before half-time. A well-worked sequence culminated in Diop finishing through the legs of Nkambadio after a clever pass from Cho, giving the home side a 1-0 lead at the break. The first…